Suvorexant: a promising, novel treatment for insomnia

Joyce K Lee-Iannotti,1 James M Parish2 1Division of Neurology, Sleep Disorders Center, Banner University Medical Center, Phoenix, AZ, USA; 2Division of Pulmonary Medicine, Center for Sleep Medicine, Mayo Clinic, Phoenix, AZ, USA Abstract: Suvorexant a novel, orexin receptor antagonist was recently...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lee-Iannotti JK, Parish JM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Suvorexant Belsomra MK-305 insomnia orexin Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/f0c588f9105d42cc928f5aef83bf3bb5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f0c588f9105d42cc928f5aef83bf3bb5
record_format	dspace
spelling	oai:doaj.org-article:f0c588f9105d42cc928f5aef83bf3bb52021-12-02T00:46:09ZSuvorexant: a promising, novel treatment for insomnia1178-2021https://doaj.org/article/f0c588f9105d42cc928f5aef83bf3bb52016-02-01T00:00:00Zhttps://www.dovepress.com/suvorexant-a-promising-novel-treatment-for-insomnia-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Joyce K Lee-Iannotti,1 James M Parish2 1Division of Neurology, Sleep Disorders Center, Banner University Medical Center, Phoenix, AZ, USA; 2Division of Pulmonary Medicine, Center for Sleep Medicine, Mayo Clinic, Phoenix, AZ, USA Abstract: Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others. Keywords: insomnia, orexin-receptor antagonist, CYP3A4, benzodiazepan receptor antagonist, MK-4305 Lee-Iannotti JKParish JMDove Medical PressarticleSuvorexantBelsomraMK-305insomniaorexinNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 491-495 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Suvorexant Belsomra MK-305 insomnia orexin Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Suvorexant Belsomra MK-305 insomnia orexin Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Lee-Iannotti JK Parish JM Suvorexant: a promising, novel treatment for insomnia
description	Joyce K Lee-Iannotti,1 James M Parish2 1Division of Neurology, Sleep Disorders Center, Banner University Medical Center, Phoenix, AZ, USA; 2Division of Pulmonary Medicine, Center for Sleep Medicine, Mayo Clinic, Phoenix, AZ, USA Abstract: Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others. Keywords: insomnia, orexin-receptor antagonist, CYP3A4, benzodiazepan receptor antagonist, MK-4305
format	article
author	Lee-Iannotti JK Parish JM
author_facet	Lee-Iannotti JK Parish JM
author_sort	Lee-Iannotti JK
title	Suvorexant: a promising, novel treatment for insomnia
title_short	Suvorexant: a promising, novel treatment for insomnia
title_full	Suvorexant: a promising, novel treatment for insomnia
title_fullStr	Suvorexant: a promising, novel treatment for insomnia
title_full_unstemmed	Suvorexant: a promising, novel treatment for insomnia
title_sort	suvorexant: a promising, novel treatment for insomnia
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/f0c588f9105d42cc928f5aef83bf3bb5
work_keys_str_mv	AT leeiannottijk suvorexantapromisingnoveltreatmentforinsomnia AT parishjm suvorexantapromisingnoveltreatmentforinsomnia
_version_	1718403531995611136

Suvorexant: a promising, novel treatment for insomnia

Ejemplares similares